Cargando…

2126. Safety, Tolerability, and Pharmacokinetics (PK) in Healthy Participants Following Single Dose Administration of Zosurabalpin, a Novel Pathogen-Specific Antibiotic for the Treatment of Serious Acinetobacter Infections

BACKGROUND: Zosurabalpin is the first representative of a novel class of tethered macrocyclic peptide antibiotics active against Acinetobacter spp., including carbapenem-resistant acinetobacter baumannii-calcoaceticus (ABC) complex organisms. This presentation summarizes and discusses unpublished pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guenther, Andreas, Millar, Laurie, Messer, Amanda, Giraudon, Mylène, Patel, Katie, Deurloo, Erik J, Lobritz, Michael, Gloge, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678405/ http://dx.doi.org/10.1093/ofid/ofad500.1749

Ejemplares similares

2109. In vitro and in vivo Killing Kinetics of Zosurabalpin (RG6006) Against Acinetobacter baumannii
por: Erbetti, Isabelle, et al.
Publicado: (2023)

2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China
por: Hawser, Stephen, et al.
Publicado: (2023)

A First Insight into Pycnoporus sanguineus BAFC 2126 Transcriptome
por: Rohr, Cristian O., et al.
Publicado: (2013)

Operating assignments in endocrine surgery training among 2126 resident participations and the Covid-19 impact: A retrospective cohort study()
por: Sarıdemir Ünal, Demet, et al.
Publicado: (2023)

2126 Optimizing a technique for visualizing retinal and choroidal blood flow noninvasively
por: Vora, Paras, et al.
Publicado: (2018)

PB2126: RETROSPECTIVE REAL LIFE STUDY OF MULTIPLE MYELOMA STATUS AT DEATH.
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Adenylylation of small RNA sequencing adapters using the TS2126 RNA ligase I
por: Lama, Lodoe, et al.
Publicado: (2016)

Background mutation in strain RB2126 affects the locomotion behavior of flp-1 mutants
por: Topalidou, Irini
Publicado: (2021)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
por: Schmitt, Christophe, et al.
Publicado: (2022)

Demographic, signs and symptoms, imaging characteristics of 2126 patients with COVID-19 pneumonia in the whole quarantine of Wuhan, China
por: Yin, Xi, et al.
Publicado: (2021)

PK-DB: pharmacokinetics database for individualized and stratified computational modeling
por: Grzegorzewski, Jan, et al.
Publicado: (2020)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

PReS-FINAL-2126: How to follow up children with Raynaud syndrome - recommendations based on the Hamburg consensus meeting 2012
por: Constantin, T, et al.
Publicado: (2013)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia
por: Zhou, Yingjie, et al.
Publicado: (2022)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

2126. Comparison of Time to Appropriate Antibiotic Between Using Microarray Assay and Mass Spectrometry Technique for Identification of Positive Blood Cultures
por: Sakulkonkij, Parichart, et al.
Publicado: (2019)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs
por: Colbert, Alex, et al.
Publicado: (2014)

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2017)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
por: Maas, Brian, et al.
Publicado: (2018)

Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

2126. Comparative Effectiveness of Infection Prevention Interventions for Reducing Procedure-Related Cardiac Device Infections: Insights from the VA CART Program
por: Asundi, Archana, et al.
Publicado: (2018)

Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

Utility of Serum EB Virus Zta Antibody in the Diagnostic of Nasopharyngeal Carcinoma: Evidences From 2,126 Cases and 15,644 Controls
por: Zhang, Guangying, et al.
Publicado: (2019)

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
por: Lorenz, K., et al.
Publicado: (2022)

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients
por: Boffito, Marta, et al.
Publicado: (2015)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_roov7gkj49llbkufa9nb9q5atr